-
- The Serum Institute of India (SII) stated the Covishield vaccine is “safe and immunogenic.”
- The affected volunteer asked for a compensation of Rs 5 crore from the SII after his health aggravated.
THDNewsDesk: On Tuesday, The Serum Institute of India (SII) stated the Covishield vaccine is “safe and immunogenic.” SII stated the incident with the Chennai volunteer was in no way influenced by the vaccine as “requisite regulatory and ethical processes and guidelines” were followed sternly.
With concerns associated with the hazardous experience reported by a volunteer in Chennai, the report by SII read, “the COVISHIELD vaccine is safe and immunogenic. The incident with the Chennai volunteer through regrettable was in no way induced by the vaccine and Serum Institute of India is sympathetic to the volunteer’s medical condition. However, we would like to clarify that all requisite regulatory and ethical processes and guidelines were followed diligently and strictly.”
The SII ensured everyone that the vaccine would not be cleared for mass use unless it is proven “immunogenic and safe.”
It further added, “Taking into considerations the complexities and existing misnomers and vaccination and immunisation; the legal notice was sent therefore to safeguard the reputation of the company which is being unfairly maligned.”
The Chennai based man asked for a compensation of Rs 5 crore from the SII after his health aggravated. The main alleged that he experienced a neurological and psychological side effect after taking a dose of COVID-19 vaccine candidate Covishield. On Sunday, The Pune based company stated there was no association between the two, further that it will seek damages over Rs 100 crore for the same.
The SII replied to the allegations that, “While the SII is sympathetic to the volunteer’s medical condition, there is no correlation with the vaccine trial and the medical condition of the volunteer. the volunteer is falsely laying the blame for his medical problems on the COVID vaccine trial.”
The SII stated that the volunteer was particularly informed, by the medical team that the complexities he underwent were independent of the vaccine test. The vaccine manufacturer stated, “It is evident that the intention behind the spreading such malicious information is an oblique pecuniary motive. The Serum Institute of India will seek damages over Rs. 100 crore for the same and will defend such malicious claims.”
The vaccine Covishield is being developed, by the UK’S Oxford University and US pharma giant AstraZeneca. The SII is a manufacturing partner for the vaccine.
